Missing Endpoints: Rare Disease Clinical Trial Design
An estimated 7,000 rare diseases impact nearly 30 million Americans and 350 million people worldwide, according to the National Organization
for Rare Disorders (NORD). This paper co-authored by ThinkGen and the Rare Advocacy Movement (RAM) looks at rare disease advocates’ relevance in clinical trial design and the consequences of non-inclusion.
Fill out the form to read our white paper
What We Value
Integrity & Passion
We care and it shows. Unwavering customer focus & commitment to excellence are intrinsic to ThinkGen.
We value empathy and active listening, and foster a collaborative environment that supports and celebrates the diverse voices of our employees.
We’re always willing to try new things and aren’t afraid to fail, because it takes perseverance to forge new paths.
We challenge ourselves daily to rethink and reimagine solutions for the obstacles our clients face.